Comparisons, Connections & Conspiracy Theories, page-354

That could be Pharma; a buying opportunity with sentiment at a low ebb and the $0.26 sp now 87% below its $2.00 sp (pre consol ) a decade ago. Odd then that none of the big investors who paid $.0.38 ps have seen the opportunity worthy of a top up since the recent 30% fall in sp.

Any upturn in investor emotion would ordinarily be linked to sp recovery. Hopefully, in everyone’s interest, we don’t have to wait too long for replacement of the incumbent Chairman. A more independently minded and relevantly experienced stewardship in a strong willed Chair less inclined to fall in line with the inflencial CEO as complained of here over the years would seem a pre-condition to sustainable change, not the least with Midkine progress.

The avoidance of more financially inept strategic decisions (e.g. the ongoing over trading risk of Advangen expansion to the US and China before any Evolis success in Australia, the costly Ikon ligation and contentious bonuses awarded by the Board to the CEO on questionable grounds) with a new Chair and a properly functioning Board that the CEO appropriately reported to with less influence, as required by a framework of sound corporate governance, would be a good starting point to recovery in sp and investor sentiment.